Immunotherapy and Antiangiogenic Therapy for the Treatment of Patients With Advanced Renal Cell Carcinoma: A Systematic Review and an Updated Network Meta-Analysis of Phase III Clinical Trials

In advanced renal cell carcinoma, few randomized controlled trials involving immunotherapy plus antiangiogenic therapy have shown survival benefits relative to Sunitinib. Our meta-analysis aimed to evaluate the efficacy and safety of combined immunotherapy and antiangiogenic therapy compared to Suni...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Rushin, Onyechi, Afoma, Mohamed, Mohamed MG, Oyenuga, Mosunmoluwa, Sartaj, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254091/
https://www.ncbi.nlm.nih.gov/pubmed/37303368
http://dx.doi.org/10.7759/cureus.38838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254091/
https://www.ncbi.nlm.nih.gov/pubmed/37303368
http://dx.doi.org/10.7759/cureus.38838

Ejemplares similares